Severe Side Effects from Yervoy (Ipilimumab)
Yervoy, a Bristol Myers Squibb immunotherapy for melanoma and other cancers, causes immune-related adverse events (irAEs) like colitis, hepatitis, and endocrinopathies. Severe (Grade 3-4) side effects occur in 25-40% of patients across clinical trials, depending on dose, combination therapy, and cancer type.[1][2]
Rates in Key Melanoma Trials
In the pivotal phase 3 trial (n=676 patients at 3 mg/kg dose), 26.4% experienced Grade 3-4 adverse events, with 15.7% treatment-related. Common severe issues included enterocolitis (7.7%), hypophysitis (4.9%), and hepatitis (1.8%).[1][3]
Higher 10 mg/kg doses saw 40-50% severe irAEs, often requiring steroids or hospitalization.[2]
Combination with Nivolumab (Opdivo)
Yervoy plus Opdivo raises severe rates to 35-55%. CheckMate 067 trial (n=945): 59% Grade 3-4 events overall, 54% treatment-related, including colitis (16%) and hepatitis (10%).[1][4]
What Counts as 'Severe'?
FDA defines Grade 3-4 as life-threatening or requiring intervention (e.g., IV steroids, infliximab for colitis). Up to 40% discontinue due to toxicity; 1-2% fatal (e.g., bowel perforation).[1][5]
Patient Risk Factors
Higher risk in those over 65, prior autoimmune disease, or combo regimens. Real-world data shows 20-30% hospitalization for irAEs.[2][6]
Management and Monitoring
Guidelines recommend baseline labs, monthly checks, and prompt steroids. Most resolve, but 10-15% have long-term issues like hypothyroidism.[3][5]
[1]: Yervoy Prescribing Information (FDA)
[2]: ASCO Post: Ipilimumab Toxicity Review
[3]: NEJM: Ipilimumab in Melanoma (Hodi et al., 2010)
[4]: NEJM: Nivolumab + Ipilimumab (Larkin et al., 2015)
[5]: NCCN Guidelines: Melanoma (v2.2023)
[6]: JAMA Oncology: Real-World Ipilimumab irAEs